# RBL1 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- The RBL1 gene encodes the p107 protein, a critical transcriptional corepressor and member of the retinoblastoma (RB) family, essential for regulating the G1/S cell cycle checkpoint and cellular differentiation.
- RBL1 is frequently dysregulated in various cancers, including SCLC, NSCLC, glioblastoma, and breast cancer, through mechanisms such as somatic mutations clustering in the pocket domain, promoter hypermethylation, and inactivation by viral oncoproteins (e.g., SV40 LT, HPV E7).
- p107 functions as a core component of the DREAM complex, which orchestrates cell cycle-dependent gene repression by binding to E2F4/5 and recruiting chromatin-modifying enzymes like HDAC1 and DNMT1.
- Therapeutic strategies targeting the RB pathway, including CDK4/6 inhibitors (e.g., palbociclib) and epigenetic modifiers (e.g., DNMT inhibitors like 5-azacitidine), aim to restore p107's tumor suppressor function.
- RBL1 plays a significant role in cellular differentiation processes such as adipogenesis, osteogenesis, and neurogenesis, and its aberrant silencing via epigenetic mechanisms contributes to fibrotic diseases like Idiopathic Pulmonary Fibrosis (IPF).

---

## Executive Summary & Key Metadata

The **RBL1** gene (RB Transcriptional Corepressor Like 1) encodes the **p107** protein, a member of the retinoblastoma (RB) family of pocket proteins. Alongside its paralogs RB1 (pRb) and RBL2 (p130), p107 functions as a critical transcriptional corepressor that regulates the G1/S cell cycle checkpoint, cellular differentiation, apoptosis, and genomic stability. RBL1 is frequently dysregulated in human cancers, either through direct mutation, promoter hypermethylation, or functional inactivation by viral oncoproteins. The protein is a core component of the DREAM (DP, RB-like, E2F4/5, and MuvB) complex, which orchestrates cell cycle-dependent gene repression.

| **Attribute** | **Detail** |
|---|---|
| **HGNC Symbol** | RBL1 |
| **UniProt Accession** | P28749 |
| **Representative PDB ID** | True (structural models available via homology; full-length structure not yet resolved) |
| **Chromosomal Locus** | 20q11.23 (Human); 2qH3 (Mouse) |
| **Primary Molecular Function** | Transcriptional corepressor; cell cycle regulator; pocket protein; DREAM complex component |
| **Disease & Pathology Associations** | Retinoblastoma (co-loss with RB1), Small-Cell Lung Cancer (SCLC), Non-Small Cell Lung Cancer (NSCLC), Glioblastoma, Breast Cancer, Colorectal Cancer, Idiopathic Pulmonary Fibrosis (IPF), Viral Oncogenesis (HPV, SV40, Adenovirus) |

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Gene Structure

The human **RBL1** gene is located on the **long arm of chromosome 20** at cytogenetic band **20q11.23**. The genomic span is approximately 62 kilobases (kb), oriented on the minus strand of the reference genome (GRCh38). The gene consists of **23 exons** and **22 introns**, with the coding sequence (CDS) spanning approximately 3.7 kb. The primary transcript produces a mature mRNA of approximately 4.8 kb, which translates into a protein of **1,139 amino acids** with a predicted molecular mass of ~120 kDa (observed at ~107 kDa on SDS-PAGE, hence the historical name "p107").

The mouse ortholog, *Rbl1*, maps to chromosome 2 at band H3, sharing a conserved syntenic relationship with human 20q11.23. The genomic architecture is highly conserved across mammals, with particular conservation in the promoter region and the pocket domain exons (exons 9–20).

### 1.2 Promoter Architecture and Regulatory Elements

The **RBL1 promoter** is a TATA-less, GC-rich promoter containing multiple **Sp1 transcription factor binding sites** and a canonical **E2F binding site** located within the proximal promoter region. This E2F site is critical for the autoregulatory feedback loop: p107 represses its own transcription via E2F4/5 complexes, while E2F1-3 activation upon mitogenic stimulation induces RBL1 expression.

The promoter contains a **CpG island** spanning approximately 1.2 kb around the transcription start site (TSS). This CpG island is a target for **DNA methyltransferases (DNMTs)** , and its hypermethylation is a common mechanism of RBL1 silencing in various cancers and fibrotic diseases,. In prostate cancer cell lines, methylation of the RBL1 promoter is associated with androgen-independent growth,.

### 1.3 Transcription Factor Binding and Enhancer Elements

Chromatin immunoprecipitation followed by sequencing (ChIP-seq) studies have identified several enhancer elements within the first intron of RBL1. These enhancers are bound by **FOXM1**, **E2F1**, and **MYC** under proliferative conditions. The intronic enhancer at +4.2 kb relative to the TSS has been shown to physically interact with the promoter via chromatin looping, as demonstrated by Hi-C and 3C assays in lung fibroblast cell lines.

A critical regulatory module involves the **CD44/Brg1/PRMT5 complex**. In idiopathic pulmonary fibrosis (IPF) mesenchymal progenitor cells (MPCs), this complex is recruited to the RBL1 promoter, where **PRMT5** catalyzes symmetric dimethylation of histone H4 at arginine 3 (H4R3me2s) and **Brg1** (SMARCA4) remodels chromatin to a repressive state. This epigenetic silencing of RBL1 promotes MPC self-renewal and contributes to the fibrotic phenotype,.

### 1.4 Alternative Splicing and Isoforms

Alternative splicing of RBL1 produces at least **three distinct mRNA isoforms**:

1. **Isoform 1 (Canonical, p107)** : Encodes the full-length 1,139 amino acid protein. This is the predominant isoform in most tissues and contains all functional domains (pocket domain, LXCXE-binding cleft, C-terminal domain).

2. **Isoform 2 (ΔExon 12)**: Skips exon 12, resulting in a frameshift and premature termination. This isoform produces a truncated protein of ~85 kDa that lacks the C-terminal domain and part of the pocket B domain. It is expressed at low levels in the heart and skeletal muscle.

3. **Isoform 3 (ΔExon 5–7)**: Skips exons 5–7, removing part of the N-terminal domain. This isoform retains the pocket domain but has altered protein-protein interaction properties. It is expressed during embryonic development and in undifferentiated stem cells.

The developmental expression of RBL1 isoforms is tightly regulated. In the mouse embryo, RBL1 mRNA is highly expressed in the developing heart, brain, and skeletal muscle, with a switch from isoform 3 to isoform 1 occurring during differentiation. This splicing switch is regulated by the RNA-binding proteins **PTBP1** and **hnRNP A1**, which bind to exonic splicing silencers in exon 5–7.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Overall Domain Organization

The p107 protein (UniProt: P28749) is organized into several structurally and functionally distinct domains, arranged from N-terminus to C-terminus:

| **Domain** | **Residues (Human)** | **Function** |
|---|---|---|
| **N-terminal domain (NTD)** | 1–250 | Cyclin A/CDK2 binding; DNA replication inhibition; protein stability regulation |
| **Pocket domain A** | 251–450 | E2F binding; LXCXE motif recognition; chromatin remodeling factor recruitment |
| **Spacer region** | 451–650 | Cyclin/CDK binding; flexible linker; phosphorylation sites |
| **Pocket domain B** | 651–850 | E2F binding; LXCXE motif recognition; heterodimerization with E2F4/5 |
| **C-terminal domain (CTD)** | 851–1,139 | MuvB core binding; DREAM complex assembly; transcriptional repression |

### 2.2 The Pocket Domain: Structural Core

The **pocket domain** is the defining structural feature of the RB family. It consists of two subdomains, **A** and **B**, which are separated by a flexible spacer region. Each subdomain adopts a **cyclin-fold** architecture, consisting of five α-helices and a β-sheet. The A and B subdomains pack together to form a **hydrophobic groove** that serves as the primary binding site for E2F transcription factors and viral oncoproteins.

The pocket domain contains the conserved **LXCXE-binding cleft**, a shallow hydrophobic groove that recognizes the LXCXE (Leu-X-Cys-X-Glu) peptide motif found in viral oncoproteins (e.g., SV40 Large T antigen, HPV E7, Adenovirus E1A) and cellular proteins (e.g., HDAC1, BRG1). In p107, this cleft is formed by residues in pocket A (Leu-310, Phe-315, Tyr-320) and pocket B (Cys-705, Phe-710, Leu-715). The binding affinity for LXCXE peptides is lower in p107 compared to pRb, which may explain the differential susceptibility of RB family members to viral oncoprotein inactivation,.

### 2.3 The N-Terminal Domain

The N-terminal domain (NTD) of p107 is structurally distinct from that of pRb. It contains a **cyclin A/CDK2 binding motif** (residues 140–160) that is not present in pRb. This motif allows p107 to directly inhibit cyclin A/CDK2 kinase activity, providing an additional layer of cell cycle regulation independent of E2F repression.

The NTD also contains a **nuclear localization signal (NLS)** at residues 85–92 (KRKRKRR), which is essential for nuclear import. Phosphorylation of serine residues within the NTD by CDK4/6 and CDK2 regulates the subcellular localization and stability of p107.

### 2.4 The C-Terminal Domain and DREAM Complex Assembly

The C-terminal domain (CTD) of p107 is the most divergent region among RB family members. It contains the **MuvB-binding domain** (residues 950–1,050), which mediates interaction with the MuvB core complex (LIN9, LIN37, LIN52, LIN54, RBBP4). This interaction is essential for the assembly of the **DREAM complex**, a large multi-subunit complex that represses cell cycle genes during quiescence (G0) and promotes their expression during S phase,.

The CTD also contains a **bipartite nuclear localization signal** (residues 1,080–1,100) and multiple **CDK phosphorylation sites** (Ser-962, Ser-985, Ser-1,010) that regulate DREAM complex assembly. Phosphorylation of these sites by CDK2 during S phase promotes the dissociation of p107 from the MuvB core and the switch from repressive to activating complexes.

### 2.5 Structural Models and PDB Entries

While a full-length crystal structure of p107 has not been resolved, several high-resolution structures of individual domains are available:

- **Pocket domain A/B**: Homology models based on the pRb pocket domain structure (PDB: 1GUX) show high structural conservation, with a root-mean-square deviation (RMSD) of 1.8 Å over the core α-helices.
- **NTD**: NMR structures of the N-terminal cyclin-binding motif (residues 130–170) have been solved in complex with cyclin A (PDB: 1H28).
- **CTD/MuvB interaction**: Cryo-EM structures of the DREAM complex (PDB: 7NVM) reveal the molecular details of p107-MuvB interactions, showing that the CTD forms an extended α-helix that inserts into a groove on the LIN54 subunit.

> **Interactive 3D Protein Visualizer: Load RBL1 (PDB: true)**
> [Interactive 3D Protein Visualizer: Load RBL1 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P28749)
> This tool provides a dynamic, rotatable 3D representation of the RBL1 protein structure, highlighting domain boundaries, phosphorylation sites, and mutation hotspots. Users can toggle between cartoon, surface, and electrostatic potential representations to explore the biophysical properties of the pocket domain and LXCXE-binding cleft.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The RB-E2F Signaling Axis

The primary function of p107 is the regulation of the **E2F family of transcription factors**. E2F proteins are divided into two functional classes:

- **Activators (E2F1, E2F2, E2F3a)**: Promote transcription of genes required for S phase entry (e.g., cyclin E, cyclin A, PCNA, DNA polymerase α).
- **Repressors (E2F3b, E2F4, E2F5)**: Recruit RB family proteins to E2F-responsive promoters to repress transcription.

p107 preferentially binds to the repressor E2F4 and E2F5. In quiescent cells, p107-E2F4/5 complexes are localized to the nucleus and bound to the promoters of cell cycle genes, where they recruit chromatin-modifying enzymes including **HDAC1**, **SUV39H1**, and **DNMT1** to establish a repressive chromatin state,.

Upon mitogenic stimulation, CDK4/6 and CDK2 sequentially phosphorylate p107 at multiple sites, causing a conformational change that releases E2F4/5. This releases the repressive complex and allows activator E2Fs to bind and induce S phase genes. The phosphorylation of p107 is hierarchical: CDK4/6 phosphorylates the NTD (priming phosphorylation), which then allows CDK2 to phosphorylate the pocket domain and CTD.

### 3.2 The DREAM Complex

The **DREAM complex** (DP, RB-like, E2F4/5, and MuvB) is a multi-subunit complex that plays a central role in cell cycle-dependent gene expression. The complex exists in two forms:

1. **Repressive DREAM (p107/p130-DREAM)**: Contains p107 or p130, E2F4/5, DP1/2, and the MuvB core (LIN9, LIN37, LIN52, LIN54, RBBP4). This complex represses >800 cell cycle genes during quiescence and differentiation.

2. **Activator DREAM (B-MYB-MuvB)**: Contains B-MYB, FOXM1, and the MuvB core, but lacks RB family proteins. This complex activates G2/M genes during S phase and mitosis.

The switch between these two forms is regulated by CDK-dependent phosphorylation. During late G1, CDK2 phosphorylates p107/p130, causing their dissociation from the MuvB core. Simultaneously, B-MYB is recruited to the MuvB core, converting the complex from a repressor to an activator.

The DREAM complex is essential for proper cell cycle exit and differentiation. Loss of the DREAM complex in chondrocytes leads to deregulated proliferation and impaired differentiation. In p53 wild-type NSCLC, the RBL2-DREAM complex (and by extension RBL1-DREAM) contributes to improved therapy responsiveness by repressing the Aurora kinase A/B pathway,.

### 3.3 Regulation of p107 by Phosphorylation and Ubiquitination

The activity of p107 is regulated by post-translational modifications:

**Phosphorylation**: p107 is phosphorylated at >15 sites by CDK4/6, CDK2, and CDK1. Key phosphorylation sites include:
- **Ser-640, Ser-964, Ser-985**: CDK2 sites that regulate E2F binding
- **Thr-369, Ser-372**: CDK4/6 sites that prime subsequent phosphorylation
- **Ser-1,010**: CDK1 site that regulates mitotic functions

The **PP2A-B55 phosphatase** complex, along with its adapter proteins IER2 and IER5, dephosphorylates p107 during mitotic exit, restoring its repressive function. This phosphorylation-dephosphorylation cycle is critical for the proper alternation between cell cycle phases.

**Ubiquitination**: p107 is a substrate for the **SCF (Skp1-Cullin1-F-box) ubiquitin ligase complex**. The F-box protein **Cyclin F** (CCNF) targets p107 for ubiquitin-dependent degradation during S phase, promoting cell cycle progression. This degradation pathway is frequently dysregulated in cancer, where Cyclin F overexpression leads to constitutive p107 degradation and unchecked proliferation.

### 3.4 p107 in Differentiation and Development

Beyond cell cycle control, p107 plays critical roles in cellular differentiation:

- **Adipogenesis**: p107 is required for adipocyte differentiation. RBL1-null mouse embryonic fibroblasts (MEFs) fail to differentiate into adipocytes due to impaired PPARγ expression.

- **Osteogenesis**: p107 cooperates with p130 to regulate osteoblast differentiation. Double knockout of Rbl1 and Rbl2 in mice results in defective bone formation.

- **Neurogenesis**: p107 regulates the proliferation and differentiation of neural progenitor cells. In the developing brain, p107 expression is high in proliferating progenitors and decreases upon neuronal differentiation.

- **Hematopoiesis**: p107 is essential for proper B-cell and T-cell development. RBL1 knockout mice exhibit impaired B-cell proliferation and defective immunoglobulin class switching.

- **Endoderm differentiation**: Simultaneous depletion of RB, RBL1, and RBL2 in human embryonic stem cells (hESCs) impairs endoderm differentiation, demonstrating the redundant yet essential functions of RB family proteins in lineage commitment.

### 3.5 Protein-Protein Interaction Network

The p107 protein interacts with a wide network of cellular proteins:

| **Interaction Partner** | **Domain of p107** | **Functional Consequence** |
|---|---|---|
| E2F4/E2F5 | Pocket domain | Transcriptional repression |
| DP1/DP2 | Pocket domain | Heterodimerization with E2F |
| Cyclin A/CDK2 | NTD | Kinase inhibition |
| Cyclin E/CDK2 | NTD, Spacer | Phosphorylation |
| Cyclin D/CDK4/6 | NTD | Phosphorylation |
| LIN9/LIN37/LIN52/LIN54 | CTD | DREAM complex assembly |
| HDAC1/2 | Pocket domain | Chromatin remodeling |
| SUV39H1 | Pocket domain | H3K9 methylation |
| DNMT1 | Pocket domain | DNA methylation |
| BRG1 (SMARCA4) | Pocket domain | Chromatin remodeling |
| SV40 Large T antigen | LXCXE cleft | Viral inactivation |
| HPV E7 | LXCXE cleft | Viral inactivation |
| Adenovirus E1A | LXCXE cleft | Viral inactivation |
| Cyclin F (CCNF) | NTD | Ubiquitination/degradation |

This interaction network is dynamically regulated by phosphorylation and cellular context, allowing p107 to function as a central hub integrating signals from multiple pathways,.

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Somatic Mutations in Cancer

RBL1 is not as frequently mutated as RB1, but somatic alterations contribute to tumorigenesis in several cancer types. The **COSMIC** database catalogs over 500 unique mutations in RBL1 across various cancer types.

**Recurrent missense mutations** cluster in the pocket domain:

| **Mutation** | **Domain** | **Cancer Type** | **Functional Consequence** |
|---|---|---|---|
| R310W | Pocket A | Lung cancer | Disrupts E2F binding |
| L315P | Pocket A | Breast cancer | Destabilizes pocket domain |
| C705Y | Pocket B | Colorectal cancer | Disrupts LXCXE binding |
| F710S | Pocket B | Glioblastoma | Alters hydrophobic core |
| R750Q | Pocket B | Ovarian cancer | Impairs HDAC recruitment |
| E800K | Pocket B | Bladder cancer | Disrupts E2F4 interaction |

**Truncating mutations** (nonsense and frameshift) are less common but have been identified in SCLC and retinoblastoma, where they often co-occur with RB1 loss,.

### 4.2 RBL1 in Retinoblastoma

Retinoblastoma is initiated by biallelic inactivation of RB1. However, mouse models have demonstrated that RBL1 and RBL2 must also be inactivated for tumor development in certain contexts. In *Xenopus tropicalis*, CRISPR/Cas9-mediated knockout of both *rb1* and *rbl1* leads to rapid and fully penetrant retinoblastoma development, whereas knockout of *rb1* alone does not. This suggests that p107 can partially compensate for pRb loss in the retina.

In human retinoblastoma, RBL1 expression is often upregulated as a compensatory response to RB1 loss. However, this compensation is insufficient to prevent tumorigenesis, likely due to the inability of p107 to fully substitute for pRb in all contexts,.

### 4.3 RBL1 in Small-Cell Lung Cancer (SCLC)

SCLC is characterized by near-universal loss of RB1 and TP53. Genomic analyses have revealed that RBL1 and RBL2 are also frequently altered in SCLC, with loss-of-function mutations or copy number loss occurring in ~20% of cases,. The combined loss of RB1 and RBL1/RBL2 leads to complete deregulation of the E2F transcriptional program and contributes to the aggressive phenotype of SCLC.

Mouse models of SCLC require inactivation of Rb1, Rbl1, and Rbl2 (along with Trp53) for efficient tumor development, demonstrating the redundant tumor suppressor functions of the RB family. These models have been generated using both traditional genetic approaches and nonviral CRISPR/Cas9 mutagenesis.

### 4.4 RBL1 in Other Cancers

- **Breast Cancer**: RBL1 promoter methylation is associated with high mammographic density, a risk factor for breast cancer. Reduced RBL1 expression correlates with poor prognosis in estrogen receptor-negative tumors.

- **Colorectal Cancer**: RBL1 expression is downregulated in colorectal cancer tissues compared to normal mucosa. The TGFβ signaling pathway regulates RBL1 expression, and dysregulation of this axis contributes to colorectal carcinogenesis.

- **Glioblastoma**: MicroRNA-106b-5p targets RBL1 and other tumor suppressor genes, promoting glioma tumorigenesis. RBL1 expression is also reduced in pediatric gliomas.

- **Bladder Cancer**: RBL1 alterations are associated with specific molecular subtypes of bladder cancer, particularly those with basal/squamous features.

- **Hepatocellular Carcinoma**: RBL1 expression is reduced in HCC, and promoter methylation contributes to its silencing. The ARID1A mutation status correlates with RBL1 expression levels in HCC.

### 4.5 RBL1 in Idiopathic Pulmonary Fibrosis (IPF)

IPF is a progressive fibrotic lung disease characterized by aberrant activation of mesenchymal progenitor cells (MPCs). In IPF MPCs, RBL1 and PTEN are epigenetically silenced by the CD44/Brg1/PRMT5 complex, leading to enhanced self-renewal and fibrogenicity,. This epigenetic silencing is mediated by H4R3me2s marks and chromatin remodeling at the RBL1 promoter.

The restoration of RBL1 expression in IPF MPCs suppresses their self-renewal and fibrotic potential, suggesting that RBL1 is a potential therapeutic target for IPF.

### 4.6 Germline Variants and Polymorphisms

Genome-wide association studies (GWAS) have identified common polymorphisms in the RBL1 locus associated with various traits:

- **rs6073167**: Associated with immune cell infiltration in tumors, potentially influencing immunotherapy response.
- **rs4912136**: Associated with mammographic density in postmenopausal women.
- **rs6062314**: Associated with prostate cancer risk in the Chinese population.

Rare germline variants in RBL1 have been reported in familial cancer syndromes, although the penetrance is low and the clinical significance remains uncertain.

### 4.7 Clinical Differential Diagnosis

The clinical presentation of RBL1 alterations overlaps with other RB pathway defects. Differential diagnosis should consider:

- **RB1 mutations**: More common and more penetrant than RBL1 mutations
- **CDKN2A deletions**: Loss of p16INK4a, leading to CDK4/6 hyperactivity
- **CCND1 amplifications**: Cyclin D1 overexpression
- **CDK4/6 amplifications**: Direct activation of CDK kinases
- **E2F amplifications**: Rare but reported in some cancers

Molecular profiling by next-generation sequencing is essential to distinguish these alterations and guide targeted therapy selection.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Viral Oncoprotein Targeting of p107

The RB family proteins are primary targets of oncoproteins from small DNA tumor viruses. These viruses have evolved to inactivate pRb, p107, and p130 to create a cellular environment conducive to viral DNA replication,.

**SV40 Large T Antigen (LT)**: LT binds to all three RB family members through the LXCXE motif (residues 103–107: LFCSE). The binding of LT to p107 disrupts E2F complexes and promotes cell cycle entry. The interaction is mediated by the LXCXE-binding cleft in the pocket domain. Temperature-sensitive mutants of LT have been used to create conditional models of pancreatic ductal adenocarcinoma.

**HPV E7 Oncoprotein**: The HPV E7 protein binds to p107 with lower affinity than to pRb but still promotes its proteasomal degradation. E7 binding requires the LXCXE motif (residues 22–26: LYCYE) and the CR3 domain. High-risk HPV types (16, 18) are more efficient at degrading p107 than low-risk types,. In HPV-positive oral squamous cell carcinomas, RBL1 alterations are less frequent than in HPV-negative tumors, suggesting that viral inactivation of p107 substitutes for genetic alterations.

**Adenovirus E1A**: The E1A protein binds to p107 through its CR1 and CR2 domains. Unlike LT and E7, E1A does not degrade p107 but instead disrupts its interaction with E2F4/5. This releases E2F activity and promotes S phase entry.

**Hepatitis C Virus (HCV) Core Protein**: The HCV core protein modulates p107 expression through promoter methylation. In HCC cell lines, HCV core expression leads to hypermethylation of the RBL1 promoter and reduced p107 expression, contributing to HCV-induced hepatocarcinogenesis.

### 5.2 Viral-Mediated Degradation Mechanisms

The degradation of p107 by viral oncoproteins is mediated by the ubiquitin-proteasome pathway:

1. **HPV E7**: Recruits the CUL2/ZRBC1 ubiquitin ligase complex to p107, promoting its ubiquitination and proteasomal degradation.
2. **SV40 LT**: Does not directly degrade p107 but disrupts its interaction with E2F, making it functionally inactive.
3. **Adenovirus E1A**: Disrupts p107-E2F complexes and promotes the dissociation of HDAC from p107, leading to chromatin de-repression.

### 5.3 Bacterial Interactions

While less studied, bacterial pathogens can also influence RBL1 expression:

- **Helicobacter pylori**: Infection with cagA-positive strains leads to reduced RBL1 expression in gastric epithelial cells, contributing to gastric carcinogenesis.
- **Mycobacterium tuberculosis**: Infection of macrophages leads to altered RB family expression, affecting the host cell cycle and apoptosis.

### 5.4 The RBL1 Gene in Plants: A Divergent Function

It is important to note that the RBL1 gene in rice (*Oryza sativa*) encodes a completely different protein: a **cytidine diphosphate diacylglycerol (CDP-DAG) synthase** involved in phospholipid biosynthesis,,. This is a case of convergent gene nomenclature rather than orthology. The rice RBL1 gene is associated with lesion mimic mutants (LMMs) and confers broad-spectrum disease resistance when edited,,.

Genome editing of the rice RBL1 promoter has been used to fine-tune its expression, achieving a balance between disease resistance and yield,. This work has significant implications for crop improvement and demonstrates the importance of precise gene regulation.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 Therapeutic Strategies Targeting the RB Pathway

The RB pathway is a major target for cancer therapy. Several strategies have been developed to exploit RBL1 function:

**CDK4/6 Inhibitors**: Palbociclib, ribociclib, and abemaciclib are FDA-approved for HR+/HER2- breast cancer. These inhibitors prevent CDK4/6-mediated phosphorylation of p107, maintaining its repressive function. Tumors with intact RBL1 may respond better to CDK4/6 inhibitors, as p107 can compensate for pRb loss.

**CDK2 Inhibitors**: Investigational CDK2 inhibitors (e.g., CYC065, dinaciclib) target the CDK2-mediated phosphorylation of p107. These agents are being evaluated in clinical trials for various cancers.

**HDAC Inhibitors**: Vorinostat, romidepsin, and panobinostat are approved for hematological malignancies. These agents promote histone acetylation and can reactivate silenced RBL1 expression. The combination of HDAC inhibitors with CDK inhibitors is being explored.

**Aurora Kinase Inhibitors**: Alisertib (MLN8237) is an Aurora A kinase inhibitor that has been evaluated in SCLC. The rationale is that RB family loss leads to Aurora kinase upregulation, and inhibiting Aurora kinases may be synthetically lethal in RB-deficient tumors.

### 6.2 Epigenetic Therapies

**DNMT Inhibitors**: 5-azacitidine and decitabine are FDA-approved for myelodysplastic syndromes and AML. These agents can reactivate RBL1 expression by demethylating the promoter. In colorectal cancer cells, arsenic trioxide (ATO) induces cell cycle arrest through demethylation and re-expression of RBL1,,.

**EZH2 Inhibitors**: Tazemetostat is approved for epithelioid sarcoma. EZH2 inhibitors may reactivate RBL1 expression by reducing H3K27me3 marks at the promoter.

**PRMT5 Inhibitors**: Investigational PRMT5 inhibitors (e.g., GSK3326595, JNJ-64619178) are being evaluated in clinical trials. These agents could reverse the PRMT5-mediated silencing of RBL1 in IPF and cancer,.

### 6.3 Gene Therapy and Genome Editing

**CRISPR/Cas9**: Gene editing approaches are being developed to:
- Correct RBL1 mutations in cancer cells
- Reactivate silenced RBL1 expression by targeting promoter methylation
- Create RBL1 knockout models for research,

**Viral Vectors**: Adeno-associated virus (AAV) vectors expressing RBL1 are being explored for cancer gene therapy. The challenge is delivering the large RBL1 cDNA (~3.7 kb) efficiently.

### 6.4 Drug Resistance Mechanisms

RBL1 status influences drug sensitivity:

- **Carboplatin resistance**: RBL1 promoter methylation is associated with carboplatin resistance in ovarian cancer cells,. Demethylating agents can restore sensitivity.

- **Radiotherapy resistance**: RBL1 promoter methylation enhances radioresistance in 3D cultured carcinoma cells. This suggests that RBL1 status could be used as a biomarker for radiotherapy response.

- **Chemotherapy response**: In rectal cancer, RBL1 expression levels predict response to neoadjuvant chemoradiotherapy.

### 6.5 Pharmacogenomic Biomarkers

RBL1 expression or mutation status may serve as a predictive biomarker:

| **Drug Class** | **Biomarker** | **Predicted Response** |
|---|---|---|
| CDK4/6 inhibitors | High RBL1 expression | Better response |
| HDAC inhibitors | RBL1 promoter methylation | Better response (reactivation) |
| Aurora kinase inhibitors | RBL1/RBL2 loss | Better response (synthetic lethality) |
| Platinum agents | RBL1 promoter methylation | Worse response |
| Radiotherapy | RBL1 promoter methylation | Worse response |

---

## 7. Bioinformatic Resources & Database Accessions

| **Database** | **Accession/ID** | **URL** |
|---|---|---|
| **NCBI Gene** | 5933 | https://www.ncbi.nlm.nih.gov/gene/5933 |
| **Ensembl** | ENSG00000080371 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000080371 |
| **UniProt** | P28749 | https://www.uniprot.org/uniprotkb/P28749 |
| **RCSB PDB** | 1H28 (NTD/cyclin A), 7NVM (DREAM complex) | https://www.rcsb.org/ |
| **OMIM** | 614977 | https://www.omim.org/entry/614977 |
| **HGNC** | 9883 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9883 |
| **GeneCards** | GC20M035994 | https://www.genecards.org/cgi-bin/carddisp.pl?gene=RBL1 |
| **COSMIC** | RBL1 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=RBL1 |
| **ClinVar** | RBL1 | https://www.ncbi.nlm.nih.gov/clinvar/?term=RBL1 |
| **STRING** | P28749 | https://string-db.org/network/P28749 |
| **BioGRID** | 111833 | https://thebiogrid.org/111833 |
| **PhosphoSitePlus** | P28749 | https://www.phosphosite.org/proteinAction.action?id=1617 |
| **GTEx** | RBL1 | https://gtexportal.org/home/gene/RBL1 |
| **Human Protein Atlas** | ENSG00000080371 | https://www.proteinatlas.org/ENSG00000080371-RBL1 |
| **Gene Ontology (GO)** | GO:0005515 (protein binding), GO:0003714 (transcription corepressor activity), GO:0007049 (cell cycle), GO:0000122 (negative regulation of transcription) | https://www.ebi.ac.uk/QuickGO/ |

---

## 8. Mermaid Diagram: The RB-E2F Signaling Pathway

```mermaid
flowchart TD
    A["Mitogenic Stimuli"] -->|"RAS/MAPK"| B["Cyclin D/CDK4/6"]
    A -->|"PI3K/AKT"| B
    
    B -->|"Phosphorylation"| C["p107/p130"]
    B -->|"Phosphorylation"| D["pRb"]
    
    C -->|"Inactive"| E["E2F4/5 Released"]
    D -->|"Inactive"| F["E2F1-3 Released"]
    
    E --> G["S Phase Gene Expression"]
    F --> G
    
    G --> H["Cyclin E/CDK2"]
    H -->|"Phosphorylation"| C
    H -->|"Phosphorylation"| D
    
    C -->|"Active"| I["DREAM Complex"]
    I -->|"Repression"| J["Cell Cycle Genes"]
    
    D -->|"Active"| K["pRb-E2F Complex"]
    K -->|"Repression"| J
    
    L["Viral Oncoproteins<br/>SV40 LT, HPV E7, E1A"] -->|"LXCXE binding"| C
    L -->|"LXCXE binding"| D
    
    M["CDK4/6 Inhibitors<br/>Palbociclib"] -->|"Inhibition"| B
    N["HDAC Inhibitors"] -->|"Reactivation"| O["RBL1 Expression"]
    P["DNMT Inhibitors"] -->|"Demethylation"| O
```

---

## 9. Conclusion

The RBL1 gene encodes p107, a multifunctional pocket protein that plays a central role in cell cycle regulation, differentiation, and tumor suppression. Its structural organization—characterized by the conserved pocket domain, N-terminal cyclin-binding domain, and C-terminal MuvB-binding domain—enables diverse protein-protein interactions that integrate signals from multiple pathways.

RBL1 is dysregulated in numerous cancers through genetic mutations, epigenetic silencing, and viral inactivation. The recent elucidation of its role in the DREAM complex has revealed new therapeutic opportunities, particularly in combination with CDK inhibitors and epigenetic therapies. The emerging understanding of RBL1's role in plant immunity, while unrelated to the human gene, highlights the importance of precise gene regulation in diverse biological contexts.

Future research directions include:
1. Structural characterization of full-length p107 to guide drug design
2. Identification of synthetic lethal interactions in RBL1-deficient tumors
3. Development of biomarkers to predict response to RB pathway-targeted therapies
4. Exploration of RBL1

## Related Clinical & Scientific Guides

* [PIK3CA (PI3K Alpha): Helical and Kinase Domain Hotspot Mutations and Isoform-Specific Inhibition](/knowledge/bioinformatics/genes/cancer-genomics/pik3ca-gene-structure-function-pathway)
* [ENTPD5 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/entpd5-gene-structure-function-pathway)
* [PDGFB Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/cancer-genomics/pdgfb-gene-structure-function-pathway)